GLP Agonist
Tirzepatide
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Preclinical and clinical data demonstrate superior weight reduction and glycemic control compared to selective GLP-1 agonists, attributable to the synergistic activation of both incretin pathways. Research models show significant reductions in body weight, adipose mass, and hepatic lipid accumulation alongside improved insulin sensitivity.
Mechanism of Action
Simultaneous agonism of GIP and GLP-1 receptors enhances insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central and peripheral pathways.
Research Applications
- → Obesity and metabolic syndrome models
- → Type 2 diabetes glycemic control studies
- → Non-alcoholic steatohepatitis (NASH) research
- → Cardiovascular risk reduction investigations
Analytical Validation
HPLC purity ≥ 98.5%; endotoxin < 1 EU/mg (LAL); sterility confirmed by USP <71>; molecular weight confirmed by ESI-MS.
For research use only